Chief Medical OfficerCIK 0001918845
| Score | Actor | Security | Side | Value | Disclosed | Evidence |
|---|---|---|---|---|---|---|
| 0 | Doyle MittieChief Medical Officer |  AVTXAvalo Therapeutics, Inc.Option exercise · 10b5-1 plan | M | $5,459 679 sh | Sep 1, 2026 traded Aug 28, 2026 | |
Doyle MittieChief Medical Officer |
| AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan |
| M |
| — 679 sh |
| Sep 1, 2026 traded Aug 28, 2026 |
| 3 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $14K 679 sh | Sep 1, 2026 traded Aug 28, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $13K 1,000 sh | Aug 19, 2026 traded Aug 17, 2026 |
| 8 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $20K 1,000 sh | Aug 19, 2026 traded Aug 17, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,000 sh | Aug 19, 2026 traded Aug 17, 2026 |
| 8 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $14K 679 sh | Aug 12, 2026 traded Aug 10, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 679 sh | Aug 12, 2026 traded Aug 10, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $5,459 679 sh | Aug 12, 2026 traded Aug 10, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $26K 1,450 sh | Jun 25, 2026 traded Jun 23, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $12K 1,450 sh | Jun 25, 2026 traded Jun 23, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,450 sh | Jun 25, 2026 traded Jun 23, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 679 sh | Jun 1, 2026 traded May 28, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $5,459 679 sh | Jun 1, 2026 traded May 28, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $11K 679 sh | Jun 1, 2026 traded May 28, 2026 |
| 20 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Grant or award | A | — 43.5K sh | May 26, 2026 traded May 21, 2026 |
| 7 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 77.9K sh | May 7, 2026 traded May 6, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 679 sh | May 7, 2026 traded May 5, 2026 |
| 3 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 28.6K sh | May 7, 2026 traded May 6, 2026 |
| 13 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $985K 77.9K sh | May 7, 2026 traded May 6, 2026 |
| 6 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $230K 28.6K sh | May 7, 2026 traded May 6, 2026 |
| 25 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $496K 27.5K sh | May 7, 2026 traded May 6, 2026 |
| 18 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $98K 5,000 sh | May 7, 2026 traded May 6, 2026 |
| 29 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $953K 44.9K sh | May 7, 2026 traded May 6, 2026 |
| 29 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $426K 19.0K sh | May 7, 2026 traded May 6, 2026 |
| 26 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $230K 10.1K sh | May 7, 2026 traded May 6, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 1,000 sh | May 7, 2026 traded May 5, 2026 |
| 3 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $13K 1,000 sh | May 7, 2026 traded May 5, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $5,459 679 sh | May 7, 2026 traded May 5, 2026 |
| 19 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $27K 1,679 sh | May 7, 2026 traded May 5, 2026 |
| 10 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $50K 3,970 sh | Apr 8, 2026 traded Apr 6, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 3,970 sh | Apr 8, 2026 traded Apr 6, 2026 |
| 16 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $72K 3,970 sh | Apr 8, 2026 traded Apr 6, 2026 |
| 23 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Open-market sale · 10b5-1 plan | SELL | $412K 25.5K sh | Mar 18, 2026 traded Mar 16, 2026 |
| 3 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 19.5K sh | Mar 18, 2026 traded Mar 16, 2026 |
| 0 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | — 5,992 sh | Mar 18, 2026 traded Mar 16, 2026 |
| 7 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $48K 5,992 sh | Mar 18, 2026 traded Mar 16, 2026 |
| 14 | Doyle MittieChief Medical Officer | AVTXAvalo Therapeutics, Inc. Option exercise · 10b5-1 plan | M | $247K 19.5K sh | Mar 18, 2026 traded Mar 16, 2026 |